A study of PTI-428 in CF Patients on Background Symdeko™ Therapy

Trial Profile

A study of PTI-428 in CF Patients on Background Symdeko™ Therapy

Planning
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs PTI 428 (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2018 New trial record
    • 14 Mar 2018 According to a Proteostasis Therapeutics media release, the company plans to initiate this trial in the second half of 2018 with initial clinical data planned for early 2019. This study is build upon the efficacy data from another study (see profile 261687).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top